Professor of Radiation Oncology, Institute for Academic Medicine
Full Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Dr. Teh is a professor and vice chair of the Department of Radiation Oncology at Houston Methodist Hospital and Weill Medical School of Cornell. Dr. Teh has contributed significantly to the field of radiation oncology – encompassing radiotherapy technology, radiation physics, molecular radiobiology and the translation of advances in these areas to clinical use. He has been instrumental in pioneering new technology in radiation oncology including APBI (accelerated partial breast irradiation), IMRT (intensity-modulated radiation therapy), IGRT (image-guided radiation therapy), SBRT (stereotactic body radiation therapy), SRS (stereotactic radiosurgery), brachytherapy as well as combined radiotherapy and gene therapy. Dr. Teh treated the first breast cancer patient in Houston with multi-lumen catheter (Contura) high dose rate brachytherapy for partial breast irradiation. This is a short course of five days irradiation, as compared to the conventional six weeks irradiation for breast cancer. Partial breast irradiation is a novel approach to spare more normal tissues.

Dr. Teh earned his medical degree from the University of Queensland in Queensland, Australia. He completed his Radiation Oncology residency, training and fellowship in IMRT at the Baylor College of Medicine in Houston, Texas. Dr. Teh is active in ASTRO (American Society of Therapeutic Radiology and Oncology), RSNA (Radiological Society of North America and ARS (American Radium Society). He is the principal investigator for RTOG (Radiation Therapy Oncology Group) at Houston Methodist Hospital. Dr. Teh has published more than 100 peer-reviewed articles on topics such as IMRT for breast cancer, editorials, 15 book chapters and a textbook on PET-CT in radiotherapy. He plays an important role in breast cancer patient care, clinical research and the education of residents and students.

Description of Research

Dr. Teh’s research focuses on the treatment of genito-urinary malignancies and unlocking the myth of radio-resistance in cancers especially renal cell carcinoma. Other research interests include Intensity modulated radiation therapy (IMRT) for prostate cancer, head and neck cancer, central nervous system tumor, pediatric cancer and breast cancer, stereotactic radiosurgery (SRS), stereotactic body radiotherapy (SBRT), stereotactic radiation therapy (SRT) and image-guided radiation therapy (IGRT), brachytherapy for prostate cancer, breast cancer and endobronchial tumors, SRS and SBRT for primary and metastatic renal cell carcinoma as well as hepatocellular carcinoma, the role of combined radiotherapy and gene therapy for cancers including prostate cancer, renal cell carcinoma, bladder cancer, pancreatic cancer, glioblastoma multiforme, cervical cancer and head and neck cancer, combining targeted therapy (AKT-inhibitor, mTOR inhibitor, tyrosine kinase inhibitor) with radiotherapy for cancer treatment, and combining oncolytic virus with radiotherapy in overcoming radio-resistant tumors in oncology.

Areas Of Expertise

Cancer stem cells Radio-resistance Prostate Movement study Post-prostatectomy IMRT Gene expression profiling in cancer Proteomics in oncology
Education & Training

Residency, Baylor College of Medicine
Clinical Fellowship, Baylor College of Medicine
MD, University of Queensland

Postmastectomy radiation therapy for triple negative, node-negative breast cancer
Haque, WM, Verma, V, Farach, AM, Butler, EB & Teh, BS 2019, Radiotherapy and Oncology, vol. 132, pp. 48-54.

Post-treatment mortality after definitive chemoradiotherapy versus trimodality therapy for locally advanced non-small cell lung cancer
Haque, WM, Verma, V, Butler, EB, Teh, BS & Rusthoven, CG 2019, Lung Cancer, vol. 127, pp. 76-83.

Postoperative chemoradiotherapy versus radiotherapy alone for elderly cervical cancer patients with positive margins, lymph nodes, or parametrial invasion
Cushman, TR, Haque, W, Menon, H, Rusthoven, CG, Butler, EB, Teh, BS & Verma, V 2018, Journal of gynecologic oncology, vol. 29, no. 6, pp. e97.

Omission of chemotherapy for low-grade, luminal A N1 breast cancer: Patterns of care and clinical outcomes
Haque, W, Verma, V, Hatch, S, Klimberg, VS, Butler, EB & Teh, BS 2018, Breast, vol. 41, pp. 67-73.

A rare presentation of choroidal metastasis from primary esophageal adenocarcinoma successfully treated with intensity-modulated radiation therapy
Date, RC, Adams, MK, Teh, BS, Schefler, AC, Musher, BL, Farach, A & Weng, CY 2018, American journal of ophthalmology case reports, vol. 11, pp. 19-22.

Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma
Qin, Q, Nan, X, Miller, T, Fisher, R, Teh, B, Pandita, S, Farach, AM, Pingali, SR, Pandita, RK, Butler, EB, Pandita, TK & Iyer, SP 2018, Radiation Research, vol. 190, no. 3, pp. 322-329.

Trends and disparities in the utilization of hypofractionated neoadjuvant radiation therapy for rectal cancer in the United States
Haque, W, Verma, V, Butler, EB & Teh, BS 2018, Journal of Gastrointestinal Oncology, vol. 9, no. 4, pp. 601-609.

Utilization of intensity modulated radiation therapy for anal cancer in the United States
Haque, W, Verma, V, Butler, EB & Teh, BS 2018, Journal of Gastrointestinal Oncology, vol. 9, no. 3, pp. 466-477.

Utilization of hysterectomy following chemoradiation for IB2/IIA2 cervical cancer in the national cancer data base
Haque, W, Verma, V, Butler, EB & Teh, BS 2018, Anticancer Research, vol. 38, no. 5, pp. 3175-3179.

Yield, techniques, and complications of transvitreal and transscleral biopsies in small uveal melanoma
Kim, RS, Chevez-Barrios, P, Divatia, M, Bretana, ME, Teh, B & Schefler, AC 2018, JAMA Ophthalmology, vol. 136, no. 5, pp. 482-488.

Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy
Haque, W, Verma, V, Hatch, S, Suzanne Klimberg, V, Brian Butler, E & Teh, BS 2018, Breast Cancer Research and Treatment, pp. 1-9.

Long-term outcome of a moderately hypofractionated, intensity-modulated radiotherapy approach using an endorectal balloon for patients with localized prostate cancer
Teh, BS, Lewis, GD, Mai, W, Pino, R, Ishiyama, H & Butler, EB 2018, Cancer communications (London, England), vol. 38, no. 1.

Omission of radiotherapy in elderly women with early stage metaplastic breast cancer
Haque, W, Verma, V, Butler, EB & Teh, BS 2018, Breast, vol. 38, pp. 154-159.

Utilization of radiotherapy and stereotactic body radiation therapy for renal cell cancer in the USA
Haque, W, Verma, V, Lewis, GD, Lo, SS, Butler, EB & Teh, BS 2018, Future Oncology, vol. 14, no. 9, pp. 819-827.

Utilization of neoadjuvant intensity-modulated radiation therapy and proton beam therapy for esophageal cancer in the United States
Haque, WM, Verma, V, Butler, EB & Teh, BS 2018, Journal of Gastrointestinal Oncology, vol. 9, no. 2, pp. 282-294.

Radiation Oncology in the Face of Natural Disaster: The Experience of Houston Methodist Hospital
Mireles, M, Pino, R, Teh, BS, Farach, A, Joseph, A & Butler, EB 2018, International Journal of Radiation Oncology Biology Physics, vol. 100, no. 4, pp. 813-815.

Clinical benefit to regionalization of care for muscle invasive bladder cancer
Haque, W, Butler, EB & Teh, BS 2018, Translational Andrology and Urology, vol. 7, pp. S98-S100.

Radiation dose in neoadjuvant chemoradiation therapy for esophageal cancer: Patterns of care and outcomes from the National Cancer Data Base
Haque, W, Verma, V, Butler, EB & Teh, BS 2018, Journal of Gastrointestinal Oncology, vol. 9, no. 1, pp. 80-89.

Trends in Cardiac Mortality in Patients With Locally Advanced Non-Small Cell Lung Cancer
Haque, W, Verma, V, Fakhreddine, M, Butler, EB, Teh, BS & Simone, CB 2018, International Journal of Radiation Oncology Biology Physics, vol. 100, no. 2, pp. 470-477.

Metaplastic Breast Cancer: Practice Patterns, Outcomes, and the Role of Radiotherapy
Haque, WM, Verma, V, Naik, N, Butler, EB & Teh, BS 2018, Annals of Surgical Oncology, pp. 1-9.